Early Lapatinib-Induced Skin Rash Predicts Better Survival With

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

Clinical management of cutaneous adverse events in patients on

Cancers, Free Full-Text

Page 1597 – Cancer Therapy Advisor

Cancers, Free Full-Text

Page 1529 – Cancer Therapy Advisor

Effects of lapatinib monotherapy: results of a randomised phase II

Trastuzumab Offers Long-Term Survival Benefits in HER2+ Early

ALTTO rash substudy CONSORT diagram. *Out of 6194 patients

PDF) Association between efficacy and skin rash following

Lapatinib as a component of neoadjuvant therapy for HER2-positive

Page 1537 – Cancer Therapy Advisor